先看重點
在51項隨機試驗、358533名參與者中,收縮壓每降低5 mm Hg,主要心血管事件減少(2型糖尿病者風險比0.94,95%置信區間0.91~0.98;無糖尿病者0.89,0.87~0.92)。糖尿病患者的相對獲益較弱,但絕對風險降低相近,且這些試驗發表於1981年至2014年。
證據類型
證據回顧
解讀依據
公開摘要
閱讀重點
方法與適用範圍
研究在問什麼
2型糖尿病患者開始降壓治療的閾值是否應與非糖尿病者不同,一直存在爭議。作者彙總主要試驗的個體參與者資料,按糖尿病狀態、基線血壓和藥物類別,比較降低收縮壓對主要心血管事件的效果。
研究對象與方法
對降壓治療試驗者協作組(Blood Pressure Lowering Treatment Trialists' Collaboration)資料集中的隨機試驗做單階段個體參與者水平資料統合分析(PROSPERO CRD42018099283)。符合條件的試驗需比較降壓藥與安慰劑或其他類別降壓藥,或強化與標準降壓策略,有基線糖尿病狀態,且每組至少有1000人年追蹤;僅納入心力衰竭、短期治療或急性情境的試驗被排除。主要結局為首次主要心血管事件(中風或腦血管病、缺血性心臟病、導致死亡或住院的心力衰竭),按收縮壓每降低5 mm Hg表示。按試驗分層的Cox模型給出按糖尿病狀態和基線收縮壓分層的風險比,Poisson迴歸估計絕對風險降低,網路統合分析比較五類降壓藥。
主要發現
以下為作者報告的結果。數值須連同族群和不確定性一起閱讀。
- 1分析納入1981年至2014年發表的51項試驗,共358533名參與者(男性佔58%),其中103325人(29%)基線時已患2型糖尿病。中位追蹤4.2年(四分位距3.0~5.0年)。
- 2收縮壓降低5 mm Hg使兩組的主要心血管事件風險都降低,糖尿病患者的相對效果較弱(風險比0.94,95%置信區間0.91~0.98),非糖尿病者為風險比0.89(95%置信區間0.87~0.92;互動作用p=0.0013)。
- 3兩組的絕對風險降低沒有明顯差別,因為糖尿病患者的絕對心血管風險更高。
- 4沒有可靠證據表明兩組中治療效果因基線收縮壓而異,五類藥物中也沒有證據顯示相對效果因糖尿病狀態而不同。
限制與不確定性
- 1試驗開展於1981年至2014年,當時的糖尿病和心血管基礎治療與現在不同。
- 2中位追蹤4.2年可能無法反映更長期的獲益或危害,摘要也未報告低血壓等不良反應。
- 3估計值按收縮壓每降低5 mm Hg計算,這是一種建模約定,假設不同試驗實際達到的降幅效果相似。
- 4本解讀僅基於摘要。
日常健康啟示
作者的結論是,有無2型糖尿病的人從降壓中獲得的絕對益處相近,因此不主張按糖尿病狀態採用不同的閾值、強度或藥物類別。這些是過去試驗的族群平均結果,你自己的目標和治療應與醫師一起決定。
如何連結自己的資料
經過驗證的上臂式血壓計是合適的工具:在每天同一時間、坐位休息後測量,並連續幾週記錄多次讀數。能估測血壓的手錶不能替代這些試驗使用的診室測量。就診時帶上家庭血壓記錄。
如何理解這類證據
先看納入了哪些設計、文獻搜尋與偏誤評估如何完成,以及搜尋截止日期;發表新不代表底層證據都是最新的。
作者的結構化摘要 English
以下英文摘要依所記錄的開放授權轉載,屬於作者原始材料,並非 MoveVitals 解讀。上方已提供研究解讀,分別說明作者結果與本站解釋;重要結論可直接查核原文。
Background
Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events by type 2 diabetes status, as well as by baseline levels of systolic blood pressure.
Methods
We conducted a one-stage individual participant-level data meta-analysis of major randomised controlled trials using the Blood Pressure Lowering Treatment Trialists' Collaboration dataset. Trials with information on type 2 diabetes status at baseline were eligible if they compared blood pressure-lowering medications versus placebo or other classes of blood pressure-lowering medications, or an intensive versus a standard blood pressure-lowering strategy, and reported at least 1000 persons-years of follow-up in each group. Trials exclusively on participants with heart failure or with short-term therapies and acute myocardial infarction or other acute settings were excluded. We expressed treatment effect per 5 mm Hg reduction in systolic blood pressure on the risk of developing a major cardiovascular event as the primary outcome, defined as the first occurrence of fatal or non-fatal stroke or cerebrovascular disease, fatal or non-fatal ischaemic heart disease, or heart failure causing death or requiring hospitalisation. Cox proportional hazard models, stratified by trial, were used to estimate hazard ratios (HRs) separately by type 2 diabetes status at baseline, with further stratification by baseline categories of systolic blood pressure (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg). To estimate absolute risk reductions, we used a Poisson regression model over the follow-up duration. The effect of each of the five major blood pressure-lowering drug classes, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β blockers, calcium channel blockers, and thiazide diuretics, was estimated using a network meta-analysis framework. This study is registered with PROSPERO, CRD42018099283.
Findings
We included data from 51 randomised clinical trials published between 1981 and 2014 involving 358 533 participants (58% men), among whom 103 325 (29%) had known type 2 diabetes at baseline. The baseline mean systolic/diastolic blood pressure of those with and without type 2 diabetes was 149/84 mm Hg (SD 19/11) and 153/88 mm Hg (SD 21/12), respectively. Over 4·2 years median follow-up (IQR 3·0-5·0), a 5 mm Hg reduction in systolic blood pressure decreased the risk of major cardiovascular events in both groups, but with a weaker relative treatment effect in participants with type 2 diabetes (HR 0·94 [95% CI 0·91-0·98]) compared with those without type 2 diabetes (0·89 [0·87-0·92]; p_(interaction)=0·0013). However, absolute risk reductions did not differ substantially between people with and without type 2 diabetes because of the higher absolute cardiovascular risk among participants with type 2 diabetes. We found no reliable evidence for heterogeneity of treatment effects by baseline systolic blood pressure in either group. In keeping with the primary findings, analysis using stratified network meta-analysis showed no evidence that relative treatment effects differed substantially between participants with type 2 diabetes and those without for any of the drug classes investigated.
Interpretation
Although the relative beneficial effects of blood pressure reduction on major cardiovascular events were weaker in participants with type 2 diabetes than in those without, absolute effects were similar. The difference in relative risk reduction was not related to the baseline blood pressure or allocation to different drug classes. Therefore, the adoption of differential blood pressure thresholds, intensities of blood pressure lowering, or drug classes used in people with and without type 2 diabetes is not warranted.
Funding
British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.
來源與署名
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, Davey Smith G, Holman RR, Woodward M, Gupta A, Adler AI, Wamil M, Sattar N, Cushman WC, McManus RJ, Teo K, Davis BR, Chalmers J, Pepine CJ, Rahimi K, Blood Pressure Lowering Treatment Trialists' Collaboration.
The lancet. Diabetes & endocrinology · 2022-07-22
DOI: 10.1016/s2213-8587(22)00172-3 ↗PubMed · 35878651 ↗Europe PMC · 所記錄的開放授權: cc by ↗摘要著作權歸原作者,依來源紀錄的開放授權轉載。中文譯文協助閱讀,英文摘要供查核術語及具體數值;本站的方法學解釋與作者結論分別呈現。
MoveVitals 編輯解讀 · 健康教育內容 · 未記錄個人臨床審閱
來源查核日期 2026-11-01
實用健康指南
放在一起讀
晝夜活動節律紊亂與更高的死亡風險相關(109,365人)
在7項觀察性研究、共109,365名參與者中,晝夜活動對比較弱(相對振幅較低)與更高的心血管死亡風險(風險比[HR]1.50,95%置信區間1.13至1.98)和全因死亡風險(HR 1.46,95%置信區間1.27至1.68)相關。證據基礎小,又是觀察性的,不能說明改善節律就能降低風險,疾病本身也可能擾亂節律。
Journal of the American Heart Association
五類運動都降低了靜息血壓,等長訓練降幅最大
彙總270項隨機試驗、共15,827名參與者的結果,有氧、抗阻、聯合、間歇和等長訓練與無介入對照組相比都降低了靜息血壓(各P<0.001),其中等長訓練降幅最大:收縮壓下降8.24 mm Hg,舒張壓下降4.00 mm Hg。各方式之間的排序部分來自間接比較,各試驗也不盡相同,所以排序不是個人的運動處方。
British Journal of Sports Medicine
鹽替代品使中國農村高危族群的中風、主要心血管事件和死亡率下降
在中國農村600個村莊、20,995名有中風史或年齡在60歲及以上且有高血壓的人中,使用鹽替代品(氯化鈉75%、氯化鉀25%)的中風發生率低於普通鹽:平均追蹤4.74年,每1000人年29.14次對33.65次(率比0.86,95%置信區間0.77至0.96;P=0.006)。死亡也更低(率比0.88),嚴重高鉀血癥事件沒有顯著增多,但試驗為開放標籤設計,且在中國農村開展。
The New England Journal of Medicine
智慧手錶脈搏不規則提醒較少見,做貼片檢查者34%確有房顫
在419,297名沒有已知心房顫動(房顫)的蘋果手錶使用者中,0.52%收到脈搏不規則提醒;返還可用心電貼片的450人中,34%確認有房顫(97.5%置信區間29至39)。提醒發出時恰有貼片記錄的,通知的陽性預測值為0.84(95%置信區間0.76至0.92),但收到提醒者中僅20.8%返還了貼片,沒有收到提醒的人未被監測,所以手錶沒有提醒並不能排除房顫。
The New England Journal of Medicine

